(Press-News.org) April 25, 2015, Vienna , Austria: Phase 3 results presented today at The International Liver Congress™ 2015 show that a combination of daclatasvir (DCV), sofosbuvir (SOF) and ribavirin (RBV) for 12 weeks was effective and well tolerated amongst patients with hepatitis C virus (HCV) infection with advanced cirrhosis and post-transplant recurrence. Sustained virologic response rates at 12 weeks (SVR12) were >90% in patients with Child-Pugh class A or B cirrhosis but lower in Child-Pugh class C. SVR12 was achieved by 94% of liver transplant recipients with HCV recurrence.
ALLY-1 is an open-label study, including treatment-naive or -experienced adults with HCV infection of any genotype.
The most common adverse events (AEs) were headache, fatigue, anaemia, diarrhoea and nausea. There were no treatment-related serious AEs. One post-transplant patient discontinued all therapy after 31 days due to headache but achieved SVR12.
INFORMATION:
About The International Liver Congress™
This annual congress is the biggest event in the EASL calendar, attracting scientific and medical experts from around the world to learn about the latest in liver research. Specialists share research studies and findings, and discuss the hottest topics related to liver disease. This year, the congress is expected to attract approximately 10,000 delegates from all corners of the globe. 2015 is a very special year for EASL and the hepatology community as they will celebrate the 50th annual meeting. The International Liver Congress™ takes place from April 22-26, 2015, Vienna, Austria.
About EASL
Since EASL's foundation in 1966, this not-for-profit organisation has grown to over 4,000 members from more than 100 countries around the world. EASL is the leading liver association in Europe, it attracts the foremost hepatology experts and has an impressive track record in promoting research in liver disease, supporting wider education and promoting changes in European liver policy.
Contact
For more information, please contact the ILC Press Office at:
ilc.press@easloffice.eu or
+44 (0)20 3580 5444
Late Breakers: Hall D
Presentation time: 17:45 - 18:00
Presenter: Fred Poordad (United States)
Abstract LO8: DACLATASVIR, SOFOSBUVIR, AND RIBAVIRIN COMBINATION FOR HCV PATIENTS WITH ADVANCED CIRRHOSIS OR POSTTRANSPLANT RECURRENCE: PHASE 3 ALLY-1 STUDY
DACLATASVIR, SOFOSBUVIR, AND RIBAVIRIN COMBINATION FOR HCV PATIENTS WITH ADVANCED CIRRHOSIS OR POSTTRANSPLANT RECURRENCE: PHASE 3 ALLY-1 STUDY
Fred Poordad* 1, Eugene R. Schiff2, John M. Vierling3, Charles Landis4, Robert J. Fontana5, Rong Yang6, Fiona McPhee7, Eric Hughes6, Stephanie Noviello6, Eugene S. Swenson7
1Texas Liver Institute, University of Texas Health Science Center, San Antonio, TX, 2Schiff Center for Liver Diseases, University of Miami Miller School of Medicine, Miami, FL, 3Baylor College of Medicine, Houston, TX, 4University of Washington School of Medicine, Seattle, WA, 5University of Michigan Medical Center, Ann Arbor, MI, 6Bristol-Myers Squibb, Princeton, NJ, 7Bristol-Myers Squibb, Wallingford, CT, United States
Introduction: The pangenotypic combination of daclatasvir (DCV) and sofosbuvir (SOF) achieves high rates of SVR in patients with chronic HCV infection. DCV+SOF has favorable safety and drug interaction profiles and a high resistance barrier. These attributes support the ALLY-1 study of DCV+SOF with ribavirin (RBV) in patients with advanced cirrhosis or post-liver transplant HCV recurrence, who have a high unmet therapeutic need.
Material and Methods: This open-label study enrolled treatment-naive or experienced adults with HCV infection of any genotype (GT) in 2 cohorts: (1) advanced cirrhosis, (2) post-liver transplant recurrence. Patients received 12 weeks of treatment with once-daily DCV 60mg + once-daily SOF 400mg and RBV (initially 600mg/d, adjusted for hemoglobin and creatinine clearance). In the cirrhosis cohort, patients transplanted during treatment could receive 12 weeks of extended treatment immediately posttransplant, regardless of treatment duration before transplant. The primary endpoint was HCV RNA 90% in patients with Child-Pugh class A or B cirrhosis but lower in Child-Pugh class C. SVR12 was achieved by 94% of liver transplant recipients with HCV.
Disclosure of Interest: F. Poordad: Grant: Conflict with: BMS, Gilead, Abbvie, Janssen, Salix, Idenix, Theravance, Achillion, Consultant: Conflict with: BMS, Gilead, Abbvie, Janssen, Salix, E. Schiff: Grant: Conflict with: Abbvie, BMS, Gilead, Merck, Orasure Technologies, Roche Molecular, Janssen Pharma, Discovery Life Sciences, Beckman Coulter, Siemens, MedMira, Conatus, Consultant: Conflict with: BMS, Gilead, Merck, Janssen Pharma, Salix, Pfizer, Arrowhead, Acorda, J. Vierling: Grant: Conflict with: BMS, Abbvie, Consultant: Conflict with: Abbvie, Gilead, Intercept, Janssen, Novartis, Roche, Merck, Sundise, C. Landis: Grant: Conflict with: Gilead, Abbvie, BMS, Janssen, R. Fontana: Grant: Conflict with: Gilead, Janssen, and BMS, Consultant: Conflict with: Chronic Liver Disease Foundation , R. Yang: Stockholder: Conflict with: BMS, Employee: Conflict with: BMS, F. McPhee: Employee: Conflict with: BMS, E. Hughes: Employee: Conflict with: BMS, S. Noviello: Employee: Conflict with: BMS, E. Swenson: Employee: Conflict with: BMS
April 25, 2015, Vienna, Austria: According to the World Health Organization, excessive alcohol drinking is the most common cause of cirrhosis worldwide. A new worldwide study presented at The International Liver CongressTM 2015 has shown the significant influence of daily drinking on this disease burden. New data shows that the cirrhosis burden caused by alcohol increased by 11.13% when moving from the moderate to heavy daily drinking (up to one drink/day for women; two drinks/day for men) classification (p END ...
April 25, 2015, Vienna, Austria: Preliminary data from an ongoing study revealed today at The International Liver Congress™ 2015 suggest that a combination of three direct-acting antivirals (DAAs) plus dasabuvir is well tolerated in patients with severe renal impairment or end-stage renal disease when used either with or without ribavirin. In addition, the combination led to rapid hepatitis C viral load suppression with no virological failures seen in the preliminary data from the ongoing open-label study.
In the study, treatment naïve non-cirrhotic adults ...
April 25, 2015, Vienna, Austria: The apparent dearth of research on hepatitis B and C testing in many European countries could be hampering efforts to identify infected individuals, according to results from a comprehensive review of 136 studies presented today at The International Liver CongressTM 2015.
The systematic review concluded that the current evidence base on hepatitis B and C testing appears to be lacking in many European countries. At present it is informed primarily by published articles and conference abstracts from just 6 out of 53 member countries of ...
April 25, 2015, Vienna, Austria: Results from a study presented today at The International Liver Congress™ 2015 demonstrate that the use of a pocket-sized ultrasound device (PUD) helps to reduce the need for further testing in both the inpatient and outpatient setting.
The study evaluated the effectiveness of the PUD when testing for the following conditions: biliary-duct dilation, gallstones, ascites, splenomegaly, pleural effusion, pericardial effusion, urinary retention, urinary stones, abdominal mass and aortic aneurysm.
PUDs offer a comparable performance ...
April 25, 2015, Vienna, Austria: Study results presented today at The International Liver Congress™ 2015 show that the occurrence of advanced liver fibrosis is similar for patients infected with the hepatitis C virus (HCV), whether or not they have been diagnosed.
Most individuals with HCV remain asymptomatic, which makes the diagnosis difficult. The study authors used the hypothesis that individuals whose HCV is not diagnosed are less likely to have advanced fibrosis than those who have been diagnosed. They then compared liver fibrosis between respondents of the ...
Barcelona, Spain: The first large international study to investigate the late side-effects of a combination of two forms of brachytherapy to treat cervical cancer has shown that the technique successfully delivers higher radiation doses to the tumour without an increase in treatment-related problems afterwards.
Brachytherapy is a type of internal radiotherapy that involves putting a radioactive source close to, or in the tumour. It is often performed after a CT or MRI scan has pinpointed the exact position of the cancer, so that the radiation treatment can be targeted ...
Depression is not linked to violence among males
Some delinquent youth with current psychiatric illness may be violent
Providing treatment could reduce violence
CHICAGO --- Most psychiatric disorders - including depression -- do not predict future violent behavior, according to new Northwestern Medicine longitudinal study of delinquent youth. The only exception is substance abuse and dependence.
"Our findings are relevant to the recent tragic plane crash in the French Alps. Our findings show that no one could have predicted that the pilot - who apparently ...
PORTLAND, Ore. - A new study released today found that drugs used to treat multiple sclerosis have soared in price in the past two decades, in some cases more than 700 percent, even though newer drugs have come to the market - a process that normally should have stabilized or reduced the cost of at least the older medications.
There are no multiple sclerosis drugs now available in the United States with a list price below $50,000 a year, which is two to three times more than the price in Canada, Australia or the United Kingdom. The group of drugs available to treat this ...
When Microsoft released the Kinect for Xbox in November 2010, it transformed the video game industry. The most inexpensive 3-D camera to date, the Kinect bypassed the need for joysticks and controllers by sensing the user's gestures, leading to a feeling of total immersion into the game. Microsoft sold 8 million Kinect units within 60 days, making it the fastest-selling electronic device ever.
"But then something interesting happened," said Oliver Cossairt, assistant professor of electrical engineering and computer science at Northwestern University's McCormick School ...
Northwestern University scientists have developed the first liquid nanoscale laser. And it's tunable in real time, meaning you can quickly and simply produce different colors, a unique and useful feature. The laser technology could lead to practical applications, such as a new form of a "lab on a chip" for medical diagnostics.
To understand the concept, imagine a laser pointer whose color can be changed simply by changing the liquid inside it, instead of needing a different laser pointer for every desired color.
In addition to changing color in real time, the liquid ...
